HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

TY - JOUR

T1 - HOVON110/ReBeL Study

T2 - Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

AU - Stevens, Wendy B.C.

AU - Bakunina, Katerina

AU - Cuijpers, Marloes

AU - Chamuleau, Martine

AU - Beeker, Aart

AU - Fijnheer, Rob

AU - Hebart, Holger

AU - Visser, Hein P.J.

AU - Doorduijn, Jeanette K.

AU - Linton, Kim

AU - Dreyling, Martin

AU - De Jong, Daphne

AU - Kersten, Marie José

N1 - Funding Information: This clinical trial is registered with EudraCT number: 2011-000097-56. The study was financially supported by the Dutch Cancer Society, Celgene and Roche. Study medication was provided by Celgene (lenalidomide), Mundipharma (bendamustine) and Roche (rituximab). Wendy B.C. Stevens, Katerina Bakunina, Aart Beeker, Marloes Cuijpers, Holger Hebart, Hein P.J. Visser, Rob Fijnheer: nothing to disclose; Marie José Kersten: research support, travel grants, honoraria or advisory boards from Celgene, research support, travel grants, honoraria or advisory boards from Roche; Jeanette K Doorduijn: Financial compensation for clinical study from, and travel costs support from Roche, travel costs support from Celgene; Daphne de Jong: advisory board and research support from Celgene; Martin Dreyling: Research support, Scientific advisory board, speaker’s honoraria from Celgene; Research support, Scientific advisory board, speaker’s honoraria from Roche; Martine Chamuleau: Research support for study from Celgene; Kim Linton: honoraria and consultation or advisory role from Roche; consultation or advisory role and sponsorship to attend conferences from Celgene. Supplemental Digital Content is available for this article. 1Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands 2HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 3Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands 4Department of Hematology, Amsterdam UMC, VU MC, Amsterdam, The Netherlands 5Department of Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands 6Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands 7Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany 8Department of Internal Medicine, Tergooi Hospital, Hilversum, The Netherlands 9Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 10Manchester Cancer Research Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom 11Department of Medicine III, University hospital, LMU Munich, Germany 12Department of Pathology, Amsterdam UMC, VU MC, Amsterdam, The Netherlands 13Department of Hematology, Amsterdam UMC, University of Amsterdam and Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands. Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. HemaSphere (2020) 4:1(e325) Received: 5 September 2019 / Received in final form: 11 November 2019 / Accepted: 14 November 2019 Citation: Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, Hebart H, Visser HPJ, Doorduijn JK, Linton K, Dreyling M, de Jong D, Kersten MJ. HOVON110/ReBeL Study: Results of the Phase I part of a Randomized Phase I/II Study of Lenalidomide, Rituximab with or without Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma. HemaSphere, 2020;4:1. http://dx.doi.org/10.1097/HS9.0000000000000325

PY - 2020/2

Y1 - 2020/2

UR - https://www.scopus.com/pages/publications/85093960763

U2 - 10.1097/HS9.0000000000000325

DO - 10.1097/HS9.0000000000000325

M3 - Letter

C2 - 32072141

AN - SCOPUS:85093960763

SN - 2572-9241

VL - 4

SP - e325

JO - HemaSphere

JF - HemaSphere

IS - 1

M1 - e325

ER -